Q1 EPS Estimate for Bio-Rad Laboratories Lowered by Analyst

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research lowered their Q1 2025 earnings estimates for Bio-Rad Laboratories in a research report issued on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $2.34 for the quarter, down from their previous forecast of $2.57. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.93 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2025 earnings at $2.87 EPS, Q3 2025 earnings at $2.94 EPS and Q3 2026 earnings at $2.90 EPS.

Several other research firms also recently weighed in on BIO. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Royal Bank of Canada upped their target price on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Citigroup raised their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $391.80.

Bio-Rad Laboratories Trading Up 2.3 %

Shares of NYSE BIO opened at $332.91 on Friday. The stock has a fifty day simple moving average of $340.52 and a 200-day simple moving average of $315.68. Bio-Rad Laboratories has a twelve month low of $262.12 and a twelve month high of $387.99. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $9.32 billion, a PE ratio of -12.18 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.85. The firm had revenue of $649.70 million during the quarter, compared to analysts’ expectations of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter last year, the company posted $2.33 EPS.

Insider Transactions at Bio-Rad Laboratories

In other news, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at approximately $2,494,016.46. This trade represents a 28.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP James Barry sold 623 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company’s stock, valued at approximately $48,582.03. This trade represents a 80.91 % decrease in their position. The disclosure for this sale can be found here. Insiders own 17.06% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BIO. First Eagle Investment Management LLC grew its holdings in shares of Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock worth $173,773,000 after buying an additional 634,311 shares during the last quarter. Swedbank AB acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth $1,824,000. Principal Financial Group Inc. grew its position in Bio-Rad Laboratories by 95.6% in the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock valued at $14,836,000 after buying an additional 21,669 shares during the last quarter. Gabelli Funds LLC increased its stake in Bio-Rad Laboratories by 16.8% in the 1st quarter. Gabelli Funds LLC now owns 41,800 shares of the medical research company’s stock valued at $14,457,000 after buying an additional 6,000 shares during the period. Finally, Mawer Investment Management Ltd. raised its position in Bio-Rad Laboratories by 63.0% during the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after buying an additional 84,237 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.